Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

THR-687 (Pan RGD integrin antagonist)

Illustration THR-687

Mode of action

THR-687, a pan RGD integrin antagonist, targets a broader spectrum of DR hallmarks. Preclinical models show that it is a potent inhibitor of angiogenesis-induced vascular leakage. The inhibition of integrins targets multiple processes involved in pathological angiogenesis and vascular leakage, unlike anti-VEGF treatment. 

Oxurion has reported positive topline data from a Phase I clinical trial evaluating THR-687 for treatment of DME. A Phase II study is planned for mid 2021, evaluating THR-687 as a VEGF-independent treatment option in the treatment of naïve DME patients. 


see full pipeline

Target indications

Diabetic retinopathy


"The promising initial data indicate that THR-687 could have the potential of being an effective monotherapy for patients with DME."

- Arshad Khanani, M.D., M.A.  - Read the press release

Clinical trials
Phase I

Phase I open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with DME


Completed - topline data reported

This Phase I study (THR-687-001 - NCT03666923) will primarily assess the safety of a single intravitreal injection of escalating dose levels of THR-687 in patients with DME. A total of 12 patients with DME have been enrolled into the US-based study ( NCT03666923). Oxurion reported positive topline data and is currently preparing to initiate a Phase II study. 


Topline data show that THR-687 is well-tolerated and safe. No dose-limiting toxicities or serious adverse events reported.

Rapid onset of action and prolonged effect on Best Corrected Visual Acuity (BCVA) seen across all doses of THR-687 following a single injection.

Phase II

Preparing start of Phase 2 study evaluating THR-687 with treatment naïve DME patients.


Preparing to initiate a Phase 2 clinical trial



Preclinical data

Preclinical studies have provided evidence that THR-687 is a potent and safe treatment, highlighting its ability to inhibit various significant stages in pathologic angiogenesis, a key factor leading to vision loss in diabetic eye disease. These preclinical data provide support for the clinical development of THR-687.

Upcoming events